Seeks to merge with or acquire a private company. Focuses on target businesses in the life sciences sector. Now — the numbers.
There is not enough trading history here to call this an established business.
If every debt were paid off today, $245.5M would still be left in the vault — a solid cushion for hard times.
The market pays 30.4× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
There is $245.5M in the vault; even if every debt were paid off, $245.5M would remain.
The stock sits at $0.13. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.